China's Consun Pharmaceutical H1 revenue rises on sales network expansion
China's Consun Pharmaceutical H1 revenue rises on sales network expansion
Overview
China pharmaceutical maker's H1 revenue rose 13.8% yr/yr to RMB1.78 bln
Net profit attributable to shareholders increased 19.5% yr/yr; basic EPS up 20.3%
Company declared interim dividend of HKD0.38 per share and repurchased 2.6 mln shares
Outlook
Company did not provide specific financial guidance or outlook for future periods
Result Drivers
SALES NETWORK EXPANSION - Co said revenue growth was mainly driven by continued efforts to expand its sales network and broaden market coverage across China
PRODUCT MIX - Strong growth in kidney medicines and hepatobiliary medicines offset declines in medical contrast medium, orthopaedics and dermatologic medicines
HIGHER GROSS MARGIN - Co attributed margin improvement to supplier management optimization, production efficiency gains and lower key raw material prices
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Net Income Attributable |
| RMB 595.31 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Consun Pharmaceutical Group Ltd is HK$24.30, about 81.3% above its August 25 closing price of HK$13.40
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago
Reuters Recommended Reads
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 24 - China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Aug 25 - China's Weigao H1 profit falls 23% as price drops, competition hit margins
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Consun Pharmaceutical
See all newsChina's Consun Pharmaceutical H1 revenue rises on sales network expansion
Brief: Consun Pharmaceutical Says Unit To Invest RMB191.4 Mln In Shanghai Huamao Pharmaceutical
Brief: Consun Pharmaceutical Group Announces Share Repurchase Program Up To HKD200 Million
Brief: Consun Pharmaceutical Logs FY Revenue RMB 3,420 Mln
Brief: Consun Pharmaceutical Says Executive Director Zhu Quan Redesignated As Non-Executive Director